Browse a category the desk has published, or search the shelf.
Listed goods
Fat loss
Cagrilintide is a long-acting, acylated amylin analogue—a pancreatic hormone—designed for once-weekly subcutaneous injection. It activates central amylin receptors, promoting satiety, slowing gastric emptying, and reducing food intake. In Phase 2 and Phase 3 clinical trials, cagrilintide induced dose-dependent weight loss, with side effects primarily being gastrointestinal in nature.
Reference priceUSD 113.00
Fat loss
This formulation combines CJC-1295 (without DAC)—a modified growth hormone-releasing hormone (GHRH) analog—with Ipamorelin, a selective growth hormone secretagogue (GHS). CJC-1295 (without DAC) produces a sustained, dose-dependent increase in GH and IGF-1 levels, while Ipamorelin selectively stimulates GH release without increasing ACTH or cortisol.
Reference priceUSD 116.00
Fat loss
Retatrutide is an investigational triple-receptor agonist peptide (targeting GLP-1, GIP, and glucagon receptors) currently under development for the treatment of obesity and type 2 diabetes. Phase II clinical trials have demonstrated significant weight loss, with patients in the high-dose group achieving a weight reduction of up to 24% over 48 weeks. This educational program outlines a once-weekly subcutaneous administration regimen, incorporating a gradual dose-escalation approach to minimize gastrointestinal side effects.
Reference priceUSD 45.00
Fat loss
Tirzepatide is a dual incretin receptor agonist composed of 39 amino acids. It activates both GLP-1 and GIP receptors, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite. With a half-life of approximately 5 days, it is convenient to administer via a once-weekly subcutaneous injection. Clinical trials have demonstrated that tirzepatide offers superior efficacy in terms of glycemic control and weight loss compared to selective GLP-1 receptor agonists.
Reference priceUSD 40.00
Fat loss
Tesamorelin is a synthetic 44-amino acid peptide analog that resembles growth hormone-releasing hormone (GHRH). It stimulates the release of endogenous growth hormone and increases IGF-1 levels, thereby promoting lipolysis and providing metabolic benefits. Tesamorelin has been approved by the FDA for the reduction of visceral adipose tissue in individuals with HIV-associated lipodystrophy.
Reference priceUSD 41.00
Checkout records one of the supported regions. Before an order moves, the concierge confirms the destination, the timing, and the cost.
RegionsUnopened goods may be raised within 14 days of delivery. Keep the order number and send it to the Grayhub desk or the WhatsApp staff.
RegionsOnline service and after-sales are answered 24 hours a day by the Grayhub desk and by WhatsApp staff. Include the order number.